NervGen Pharma Corp. (TSXV: NGEN)

Canada flag Canada · Delayed Price · Currency is CAD
2.980
+0.050 (1.71%)
Jan 20, 2025, 3:59 PM EST
17.79%
Market Cap 209.52M
Revenue (ttm) n/a
Net Income (ttm) -24.01M
Shares Out 70.31M
EPS (ttm) -0.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,651
Average Volume 61,605
Open 2.920
Previous Close 2.930
Day's Range 2.920 - 2.980
52-Week Range 1.650 - 3.980
Beta 1.39
RSI 50.25
Earnings Date Feb 27, 2025

About NervGen Pharma

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer’s disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cor... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Employees 7
Stock Exchange TSX Venture Exchange
Ticker Symbol NGEN
Full Company Profile

Financial Performance

Financial Statements

News

NervGen In Spotlight As It Approaches Clinical Proof Of Concept Readout For Spinal Cord Regeneration

NervGen completed enrollment for its phase 2 trial in spinal cord injury, setting the countdown for topline results in Q2, 2024. The research suggests that the company may have a solution for nervous ...

11 days ago - Seeking Alpha

NervGen Completes Enrollment in Chronic Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

Topline data from the chronic cohort is expected in Q2 2025 Institutional Review Board (IRB) protocol amendment changes approved, and screening has been initiated for subacute cohort This news release...

18 days ago - Newsfile Corp

Undercovered Dozen: OppFi, PowerFleet, Eletrobras, American Battery +

Discover twelve undercovered stocks with potential like American Battery Technology, Quantum Corporation, and NervGen Pharma Corp.

23 days ago - Seeking Alpha

NervGen: Data For Spinal Cord Injury Treatment Candidate Likely For Mid-2025

NervGen's NVG-291 shows promising preclinical results in spinal cord injury, with significant improvements in motor function and nerve regeneration, positioning it as a potential breakthrough in nervo...

27 days ago - Seeking Alpha

NervGen Announces "At-The-Market" Equity Program

Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biotech company dedicated to develop...

4 weeks ago - Newsfile Corp

NervGen Pharma GAAP EPS of -$0.07

2 months ago - Seeking Alpha

NervGen Pharma Reports Q3 2024 Financial Results and Operational Updates

Target enrollment in the chronic cohort of our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury (SCI) is approaching completion NVG-300 preclinical test-of-concept studies ...

2 months ago - Newsfile Corp

NervGen Pharma to Present at the Stifel 2024 Healthcare Conference

Vancouver, British Columbia--(Newsfile Corp. - November 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeut...

2 months ago - Newsfile Corp

NervGen Pharma Provides Update on Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

Target enrollment in the chronic cohort close to completion Vancouver, British Columbia--(Newsfile Corp. - September 30, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biot...

4 months ago - Newsfile Corp

NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th Annual Science & Advocacy Symposium Focused on Spinal Cord Injury

Vancouver, British Columbia--(Newsfile Corp. - September 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for...

4 months ago - Newsfile Corp

NervGen Pharma to Present at the 63rd International Spinal Cord Society Annual Scientific Meeting

Vancouver, British Columbia--(Newsfile Corp. - September 16, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for...

4 months ago - Newsfile Corp

NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for th...

5 months ago - Newsfile Corp

NervGen Pharma reports Q2 results

5 months ago - Seeking Alpha

NervGen Pharma Reports Q2 2024 Financial Results and Operational Updates

Targeting to complete enrollment in the Phase 1b/2a chronic cohort in Q3 2024 Protocol being amended to enhance enrollment and lessen burden on participants in the subacute cohort NVG-300 advanced int...

5 months ago - Newsfile Corp

NervGen Pharma to Present at the Canaccord Genuity 44th Annual Growth Conference

Vancouver, British Columbia--(Newsfile Corp. - August 6, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the...

5 months ago - Newsfile Corp

NervGen Pharma Grants Stock Options

Vancouver, British Columbia--(Newsfile Corp. - August 2, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) a clinical stage biotech company dedicated to developing innovative solutions for the ...

6 months ago - Newsfile Corp

NervGen Pharma Appoints Neil Klompas to Board of Directors

Seasoned pharmaceutical executive with extensive experience in high-growth life sciences companies joins NervGen Leadership appointment supports the company's mission to advance NVG-291 after the comp...

6 months ago - Newsfile Corp

NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage

New molecule demonstrates efficacy in a challenging SCI model Expanding pipeline into new indications of ischemic stroke and ALS Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - NervGen...

7 months ago - Newsfile Corp

NervGen Pharma to Present at the 2nd Annual Spinal Cord Injury Investor Symposium

Vancouver, British Columbia--(Newsfile Corp. - June 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the ...

7 months ago - Newsfile Corp

NervGen Pharma Announces Results of Annual General Meeting of Shareholders

All resolutions submitted for approval were passed by shareholders Glenn Ives appointed as Chair of the Board John Ruffolo appointed as Chair of the Audit Committee Vancouver, British Columbia--(Newsf...

8 months ago - Newsfile Corp

NervGen Pharma to Present Two Posters at the American Spinal Injury Association 51st Annual Scientific Meeting

Vancouver, British Columbia--(Newsfile Corp. - May 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the t...

8 months ago - Newsfile Corp

NervGen Pharma Reports Q1 2024 Financial Results and Operational Updates

Target for completing enrollment of the chronic cohort in the Phase 1b/2a clinical trial moved to Q3 2024 Subacute cohort protocol being amended to enhance feasibility and lessen burden on participant...

8 months ago - Newsfile Corp

NervGen Files Management Information Circular and Announces Board of Directors Transition

Bill Radvak to transition to Board Advisor following decision to not stand for re-election to NervGen's Board of Directors Annual General Meeting of Shareholders to be held on June 4, 2024 Vancouver, ...

9 months ago - Newsfile Corp

NervGen Engages Russo Partners LLC to Provide Public Relations Services

Vancouver, British Columbia--(Newsfile Corp. - April 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing...

9 months ago - Newsfile Corp

NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates

Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024 CA$23 million bought deal financing completed in March 2024 provides expected cash runway throug...

9 months ago - Newsfile Corp